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Neutrophils play an important role in the control of viral infections by releasing a variety of potent agents. We previously
demonstrated that Epstein–Barr virus (EBV) binds to human neutrophils and stimulates cytokine synthesis including interleu-
kin-1 (IL-1) and IL-1 receptor antagonist (IL-1Ra). Since neutrophil functions are known to be modulated by the priming
effect of granulocyte –macrophage colony-stimulating factor (GM-CSF), we therefore investigated the cellular source of GM-
CSF synthesis following treatment of leukocytes with EBV and the effect of GM-CSF on the production of IL-1, IL-1Ra, and
superoxide by EBV-treated neutrophils. In enriched-cell populations, only monocytes were found to produce GM-CSF in
response to EBV, which was maximal after 12 h of incubation. The results obtained with UV-irradiated particles or EBV
neutralized with monoclonal antibody 72A1 suggest that contact between the cell and the gp350 of the viral envelope is
sufficient to induce the release of GM-CSF. On the other hand, GM-CSF differentially upregulated EBV-induced IL-1 and IL-
1Ra production by neutrophils. Pretreatment of neutrophils with GM-CSF prior to EBV activation synergistically enhanced
the production of IL-1a and IL-1b, but only marginally affected IL-1Ra synthesis. In addition, GM-CSF was also found to
synergistically enhance the superoxide production by neutrophils in response to EBV. Molecular analysis showed that GM-
CSF did not alter the IL-1b and IL-1Ra mRNA synthesis induced by EBV, suggesting that GM-CSF could act at a posttransla-
tional level. Local production of GM-CSF by monocytes in tissues invaded by EBV could serve to potentiate the host defense
mechanisms directed toward the destruction of the infectious virus. q 1997 Academic Press
INTRODUCTION be involved in the regression or the outgrowth of EBV-
infected B cells (Gosselin et al., 1992a,b, 1989; Lotz et
Epstein–Barr virus (EBV), a human herpesvirus, is al., 1986; Whittingham et al., 1993). In contrast, IL-6 and
known to cause infectious mononucleosis (IM) and is granulocyte–macrophage colony-stimulating factor (GM-
closely associated with nasopharyngeal carcinoma, Afri- CSF) were found to enhance the emergence of EBV-
can Burkitt’s lymphoma, and also B-cell lymphomas ob- transformed B cell lines (Paul and Bauman, 1990; Tosato
served in some immunocompromised patients. However, et al., 1990). The production of these mediators could
the cellular events as well as the mediators involved then be responsible for the onset of many of the clinical
in the immune regulation of EBV infection are not fully symptoms and morphological features characteristic of
elucidated. the EBV-associated infectious disease.
Several lines of evidence indicate that cytokines could Among these cytokines, GM-CSF is of particular inter-
play an important role in the pathogenesis associated est for its biological properties on the nonspecific de-
with EBV. For example, elevated levels of interleukin (IL)- fense mechanisms mediated by phagocytes such as
1, IL-2, IL-6, and interferon (IFN) g were detected in the neutrophils and monocytes. GM-CSF induces the prolif-
serum of patients with IM (Hornef et al., 1995; Linde et al., eration of granulocytes and monocyte/macrophage pre-
1992). Furthermore, IL-1b, IL-2, IL-6, and tumor necrosis cursor cells. In addition, GM-CSF directly activates and
factor (TNF) a and b gene expression was enhanced primes functional properties of mature phagocytes. In
in tonsils and in lymph nodes of EBV-infected patients fact, direct activation of polymorphonuclear neutrophils
(Andersson and Andersson, 1993; Devergne et al., 1991; with GM-CSF results in the production of IL-1, IL-1 recep-
Foss et al., 1994). Similarly, these patterns of cytokine tor antagonist (IL-1Ra), IL-6, IL-8, and melanocyte growth-
production were supported by in vitro studies suggesting stimulatory activity and induces the tyrosine phosphory-
that some mediators such as IL-1, IL-2, and IFNg may lation of various proteins (Beaulieu and McColl, 1994;
Cicco et al., 1990; Hachicha et al., 1995; Lindemann et
al., 1988, 1989; McColl et al., 1991; Roberge et al., 1994).1 To whom reprint requests should be addressed at the Laboratory
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and the neutrophil respiratory burst in response to subse- centrated viral preparations were resuspended in RPMI
1640, aliquoted, and stored at 0807C until used. Viralquent stimulation (Hachicha et al., 1995; Rapoport et al.,
1992; Roberge et al., 1994; Ruef and Coleman, 1990). titers [107 transforming units (TFU)/ml] were determined
as previously described (Menezes et al., 1975). The pres-Several lines of evidence suggest that GM-CSF could
also play a physiologic role in viral infection. For example, ence of IL-1a, IL-1b, IL-1Ra, IL-8, MIP-1a, or GM-CSF,
as assessed by specific ELISA, was not detected in theincreased levels of GM-CSF protein were detected in
plasma of patients infected with HIV (Hober et al., 1993). EBV preparations used. UV-irradiated (1 h, 265 nm) and
heat-inactivated (1 h at 567C) viral preparations were alsoReplication of HIV was suppressed in monocyte-derived
macrophage induced by GM-CSF (Matsuda et al., 1995), tested. The neutralizing monoclonal antibody 72A1
(ATCC, Rockville, MD) and the nonneutralizing antibodywhich was also found to exert a protective activity against
Sendai virus and herpes simplex virus infections in mice 2L10 (both directed against the viral envelope of EBV)
were utilized to evaluate the specificity of the response(Azuma et al., 1992; Iida et al., 1989).
In previous studies aimed at investigating virus – obtained with EBV.
phagocyte interactions, we demonstrated that EBV binds
to the surface of monocytes and modulates expression Purification of monocytes and lymphocytes
of cytokine genes such as IL-1 and IL-6 (Gosselin et al.,
1992b, 1991). In contrast, EBV has a direct inhibitory ef- Venous blood from healthy medication-free volunteers
was collected under sterile conditions on citrate/phos-fect on TNFa production by human monocytes (Gosselin
et al., 1991). We also recently reported that EBV binds to phate/dextrose/adenine anti-coagulant solution. Periph-
eral blood mononuclear cells (PBMC) were purified byhuman neutrophils, causes functional alterations of these
cells (such as cellular aggregation and priming of respi- means of 6% dextran sedimentation followed by standard
techniques of Ficoll–Paque gradient. The viability ex-ratory burst activity), and induces the production of IL-1
and of its natural receptor antagonist, IL-1Ra (Beaulieu ceeded 98% as detected by the trypan blue exclusion
test. Enriched monocyte and lymphocyte suspensionset al., 1995; Roberge et al., 1996).
The present study was initiated to investigate the cellu- were obtained by centrifugation of PBMC over Percoll
gradients as previously described (Surette et al., 1996).lar source and the effect of GM-CSF on the EBV-induced
superoxide production and synthesis of IL-1 and IL-1Ra Briefly, Percoll gradients were prepared by mixing 9 vol-
umes of Percoll at a density of 1.075 g/ml with 1 volumeby human neutrophils.
101 concentration of HBSS. Density and pH of the final
Percoll solution were adjusted to 1.066 g/ml and 7.4,MATERIALS AND METHODS
respectively. PBMC (20 1 106) were layered on the Per-
Materials coll cushions and centrifuged at 400 g for 20 min at 227C.
The purified monocytes were recovered in the upperFicoll – Paque, Dextran T-500, and Percoll were from
broad band while the purified lymphocytes were in thePharmacia (Dorval, Que´bec, Canada). Hanks’ balanced
cell pellet. The cells were then washed twice in HBSS.salt solution (HBSS), HEPES buffer, RPMI 1640, and
The purity of each cell population was evaluated by cy-fetal bovine serum (FBS) were from Gibco Labs (Grand
tometry using anti-CD2, anti-CD3 (T cells), anti-CD19 (BIsland, NY). Diff-Quick stain kit was from Baxter Scien-
cells), and anti-CD14 monoclonal antibodies (Becton –tific Products (McGaw, IL). Biosynthetic human recom-
Dickinson, San Jose, CA). Final monocyte and lympho-binant GM-CSF was a generous gift from the Genetics
cyte preparations used in this study were 85 and 99%,Institute (Cambridge, MA). The GM-CSF was stored as
respectively.a stock solution of 100 nM in PBS containing 0.01%
PBMC (107/ml), monocytes (106/ml), and lymphocytesBSA (Sigma). At the highest concentration used, GM-
(106/ml) were suspended in RPMI 1640 containing 5%CSF had levels of endotoxin contamination 0.27 pg/
FBS and incubated with or without EBV (105 TFU/ml) orml, as determined by the amebocyte lysate assay (Whit-
5 mg lipopolysaccharide (LPS) for the indicated period oftaker, Walkersville, MD).
time at 377C. At the end of the incubation period, the
cell-free supernatants were collected after centrifugationVirus preparation
and immediately stored at 0207C until assayed for GM-
CSF content. The cell pellets were extensively washedViral preparations of EBV strain B95-8 were produced
as previously described (Beaulieu et al., 1995). Briefly, in HBSS, centrifuged, resuspended in 1 ml incubation
medium, subjected to two cycles of freeze/thaw, and fi-B95-8 (mycoplasma free) were grown in RPMI 1640 me-
dium supplemented with 10% heat-inactivated FBS. nally sonicated for 15 s. Cell-free supernatants were then
collected after centrifugation and stored at 0207C untilWhen the viability of the cells was found to be less than
20%, cell-free culture supernatants were harvested and tested for cell-associated GM-CSF. GM-CSF quantifica-
tion was performed immediately following preparation offiltered through a 0.45-mm pore size filter, and the viral
particles were concentrated by ultracentrifugation. Con- the cell-associated materials.
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Neutrophil preparation for the elaboration of the IL-1a ELISA equally recognize
the 31-kDa precursor form and the 17-kDa processed
Venous blood from healthy medication-free volunteers form of IL-1a (Grassi et al., 1991). The monoclonal anti-
was collected under sterile conditions on citrate/phos- bodies used for the elaboration of the IL-1b ELISA detect
phate/dextrose/adenine anti-coagulant solution. Neutro- the 17-kDa mature form of IL-1b, but underestimate its
phils were purified by means of 6% dextran sedimenta- 31-kDa precursor form. Part of the cell-associated materi-
tion followed by standard techniques of Ficoll–Paque als was thus treated with chymotrypsin in order to detect
gradient and hypotonic lysis of erythrocytes. Neutrophils the majority of the 31-kDa precursor form of IL-1b. We
were resuspended in incubation medium (RPMI 1640 used for IL-1Ra measurements a commercially available
supplemented with 5% FBS) at a final concentration of EIA kit (minimal detection limit of 17 pg/ml) purchased
107 cells/ml. Differential counts on neutrophil fractions from R&D Systems (Minneapolis, MN), and for GM-CSF
were carried out with Diff-Quick and nonspecific ester- measurements, an EIA kit (minimal detection limit of 2 pg/
ase staining. Final neutrophil preparations used in this ml) from Biosource International (Camarillo, CA). Neither
study were 98% pure and only the preparations con- assay cross-reacted significantly with known human cy-
taining less than 21 104 monocytes/107 cells were used. tokines.
Significant levels of IL-1 and IL-1Ra were only detected
when 6 1 104 purified monocytes or more were incu-
Isolation of total RNA and Northern blot analysis
bated in the presence of EBV (Roberge et al., 1996). In
addition, no IL-1Ra was detected when the neutrophil Neutrophils were preincubated with or without GM-
preparations were incubated in the presence of adherent CSF for 1 h and further incubated with EBV for 3 h before
human IgG, a known powerful activator of IL-1Ra produc- RNA extraction. Isolation of total cellular RNA and North-
tion by monocytes (Surette et al., 1996). Cell viability was ern blots were performed as previously described (Rob-
98% as evaluated by trypan blue exclusion and lactate erge et al., 1996). The membranes were hybridized with
dehydrogenase activity. cDNA probes radiolabeled by random priming (Boeh-
Freshly purified blood neutrophils (107) were preincu- ringer Mannheim) with [a-32P]CTP (3000 Ci/mmol sp act).
bated in 5-ml polypropylene tubes (12 1 75 mm; Fisher For IL-1b and IL-1Ra probing, we used the 1.3-kb cDNA
Scientific, Montre´al, Que´bec, Canada) with GM-CSF or fragment of the PSP64 plasmid and the 1.8-kb cDNA
with equivalent volumes of the appropriate diluents at fragment cloned into the EcoRI site of a PGEM2 .
377C for the indicated period of time. Optimal enhance-
ment of EBV-induced IL-1 and IL-1Ra production was Superoxide production
observed with neutrophils preincubated with 1 nM GM-
Superoxide production was monitored as describedCSF (data not shown). Doses in the range of this concen-
by Naccache and colleagues (Gilbert et al., 1992) as thetration were also used in in vivo studies (for review, see
(superoxide dismutase sensitive) reduction of cyto-Gasson, 1991). These cells were further incubated with
chrome c. Briefly, neutrophil suspensions (107/ml) wereor without EBV in a humidified 5% CO2 incubator at 377C.
preincubated with or without 500 pM GM-CSF for 30 minAt the end of each incubation period, the cell-free super-
at 377C. The cells were then diluted to 2 1 106/ml withnatants were collected after centrifugation and immedi-
prewarmed (377C) incubation medium and further incu-ately stored at 0207C until assayed for IL-1a, IL-1b, or
bated with or without EBV or 1007 M fMLP in the presenceIL-1Ra content. The cell pellets were extensively washed
of 130 mM cytochrome c for the indicated time at 377C.in HBSS, centrifuged, resuspended in 1 ml incubation
After appropriate stimulation, the reactions were stoppedmedium, subjected to two cycles of freeze/thaw, and fi-
by transferring the tubes to an ice-cold bath, followednally sonicated for 15 s. Cell-free supernatants were then
by centrifugation. The absorption of cytochrome c wascollected after centrifugation and stored at 0207C until
monitored at 540 and 550 nm, and the amount of superox-tested for cell-associated IL-1a, IL-1b, or IL-1Ra. IL-1
ide produced was calculated from the difference in opti-and IL-1Ra quantifications were performed immediately
cal densities of the two wavelengths using an extinctionfollowing preparation of the cell-associated materials.
coefficient of 21.1.
Enzyme immunoassays for immunoreactive IL-1a,
IL-1b, IL-1Ra, and GM-CSF RESULTS
The assessment of IL-1a and IL-1b in supernatants Kinetics of GM-CSF production by human
and cell-associated materials was performed using two mononuclear cells in response to EBV
sensitive and specific enzyme immunometric assays with
acetylcholine esterase as label, elaborated by Grassi et Mononuclear cells isolated from the peripheral blood
of three healthy volunteers were incubated with or with-al. (1989, 1991). The detection limit for both IL-1a and IL-
1b was 2 pg/ml without any significant cross-reactivity out EBV for increasing periods of time, and total GM-
CSF was assessed by a specific ELISA. A representativewith other cytokines. The monoclonal antibodies used
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TABLE 2
Effect of EBV on GM-CSF Production by Purified Monocytes,
Lymphocytes, or Neutrophils
Total GM-CSF production (pg/ml)
Donor Monocytes Lymphocytes Neutrophils
Unstimulated 1 ND ND ND
2 25 ND ND
3 74 ND ND
EBV 1 100 ND ND
2 275 ND ND
3 369 ND ND
LPS 1 463 20 ND
2 666 33 ND
3 456 11 ND
FIG. 1. Kinetics of GM-CSF production by human mononuclear cells Note. Neutrophils (107/ml), monocytes (106/ml), or lymphocytes (106/
in response to EBV. Peripheral blood mononuclear cells (107) were ml) were incubated with or without EBV or 5 mg/ml LPS for 24 h at
incubated with or without EBV for the required period of time at 377C. 377C. Total (secreted / cell-associated) GM-CSF was assessed by
Total immunoreactive (cell-associated / secreted materials) GM-CSF specific ELISA. ND, not detectable.
was assessed by a specific ELISA. Results are from one experiment
and are representative of three other separate experiments.
incubated with or without EBV or with 5 mg/ml LPS for
24 h at 377C, and total GM-CSF production was assessedexperiment is shown in Fig. 1. Mononuclear cells incu-
by a specific ELISA. Incubation of monocytes with EBVbated in medium alone for up to 24 h produced low levels
increased the production of GM-CSF compared to un-of GM-CSF. A time-dependent production of GM-CSF
stimulated monocytes (Table 2). In contrast, EBV failedwas observed in response to incubation with EBV. Signifi-
to trigger the production of GM-CSF in lymphocytes orcant production of GM-CSF was detected after 6 h and
neutrophils. Although neutrophils did not synthesize GM-reached a maximal level after 12 h of culture. Further-
CSF in response to EBV or LPS, the same neutrophilmore, more than 90% of GM-CSF synthesized by mono-
preparations were found to synthesize IL-1 and IL-1Racytes was secreted (data not shown). Specificity of EBV-
in response to EBV (data not shown).induced GM-CSF synthesis by human monocytes was
also tested. As shown in Table 1, UV-irradiated EBV was
Time-dependent effect of GM-CSF on EBV-inducednot found to affect the production of GM-CSF, in contrast
IL-1 and IL-1Ra production by neutrophilsto monocytes treated with heat-inactivated EBV. Pre-
incubation of EBV with the neutralizing antibody 72A1 Neutrophils were preincubated with or without GM-
also inhibited the GM-CSF synthesis. Preincubation with CSF for the desired period of time and further treated
the nonneutralizing antibody 2L10 had no effect on infec- with EBV for 6 h [optimal incubation time (Roberge et
tious EBV. al., 1996)]. Optimal enhancement of IL-1b and IL-1Ra
production in response to EBV was observed when neu-
Cellular source of EBV-induced GM-CSF synthesis
trophils were preincubated with 1 nM GM-CSF for 1 h
prior to incubation in the presence of EBV. Similar resultsWe next investigated the effect of EBV on the produc-
tion of GM-CSF by purified lymphocytes, monocytes, and were obtained when the production of IL-1a was investi-
gated (data not shown). Total IL-1b and IL-1Ra produc-neutrophils. These cells were purified from the peripheral
blood of three healthy volunteers. The purified cells were tion was assessed by specific ELISAs. As previously re-
TABLE 1
Effect of Inactivated EBV on GM-CSF Synthesis by Human Monocytes
Unstimulated EBV HI-EBV UV-EBV 72A1-treated EBV 2L10-treated EBV
23 { 6 248 { 39 34 { 8* 296 { 27 41 { 7* 287 { 36
Note. Enriched monocytes (106/ml) were incubated with infectious or inactivated EBV for 24 h at 377C. Neutralizing (72A1) and nonneutralizing
(2L10) monoclonal antibodies were also incubated with infectious EBV for 1 h at 377C before cellular treatment. Results are expressed in pg/ml
and are the means of three separate experiments.
* Data significantly different from EBV-treated cells (P  0.05).
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h at 377C, and cell-associated and secreted IL-1a, IL-1b,
and IL-1Ra were assessed (Table 3). GM-CSF was found
to differentially modulate the EBV-induced production of
IL-1 and IL-1Ra in neutrophils. Preincubation of neutro-
phils with GM-CSF synergistically enhanced the produc-
tion of IL-1a and IL-1b by neutrophils in response to EBV.
Indeed, the total amount of IL-1a and IL-1b produced
by EBV-treated neutrophils was significantly increased
(154%) when neutrophils were preincubated with GM-
CSF before EBV treatment. GM-CSF moderately en-
hanced the IL-1Ra production by neutrophils treated with
EBV. Although GM-CSF enhanced the production of IL-
1 by neutrophils in response to EBV, more than 94% of
the IL-1a and IL-1b produced remained cell-associated.
The specificity of the enhancing effect of GM-CSF was
evaluated by using a neutralizing antibody to GM-CSF.
Pretreatment of GM-CSF with neutralizing anti-GM-CSF
polyclonal antibody (Genetics Institute) abrogated the IL-
1 and IL-1Ra production induced by GM-CSF alone (neu-
tralized GM-CSF: IL-1, 19 { 5; IL-1Ra, 28,595 { 4033)
and the enhancement of EBV-induced IL-1 and IL-1Ra
production by GM-CSF (neutralized GM-CSF / EBV: IL-
1, 826 { 91; IL-1Ra, 49,110 { 4812).
GM-CSF upregulates the production of superoxide by
neutrophils in response to EBV
To eliminate invading microorganisms, neutrophils use
microbicidal processes, the best known being the respi-
ratory burst activity. In a previous study, EBV was found toFIG. 2. Effect of preincubation time of neutrophils with GM-CSF on
the IL-1b and IL-1Ra production in response to EBV. Neutrophils (107/ prime human neutrophils in the induction of superoxide
ml) were incubated with or without 1 nM GM-CSF for the required release (Beaulieu et al., 1995). Since GM-CSF is known
period of time at 377C and further incubated with or without EBV for 6 to enhance the release of superoxide (Gasson, 1991) inh. Total immunoreactive (cell-associated / secreted materials) IL-1b
neutrophils, we next evaluated the effect of GM-CSF onand IL-1Ra were assessed by a specific ELISA. Results are from one
the EBV-induced superoxide production. Neutrophilsexperiment and are representative of three other separate experiments.
In cell cultures treated with GM-CSF alone, concentrations of IL-1b from three separate individuals were preincubated with
and IL-1Ra detected were 90 pg/ml and 20 ng/ml, respectively. or without 500 pM GM-CSF for 1 h at 377C and further
stimulated with EBV for 1 h. These conditions were opti-
mal for superoxide production studies in human neutro-ported (Roberge et al., 1994, 1996), freshly isolated neu-
phils. The results are shown in Table 4. GM-CSF wastrophils contained constitutive levels of IL-1Ra but no IL-
found to induce the production of superoxide anions in1b proteins, which were not significantly modified by
neutrophils. In contrast, EBV by itself did not significantlyculture medium. However, neutrophils synthesized IL-
affect the superoxide production. Pretreatment of neutro-1b and IL-1Ra in response to EBV (Fig. 2). In addition,
phils with GM-CSF enhanced superoxide production in-preincubation of neutrophils with GM-CSF prior to stimu-
duced in response to EBV.lation with EBV significantly enhanced the EBV-induced
IL-1 production in a time-dependent manner (Fig. 2). With
Northern blot analysis of IL-1b and IL-1Ra productionregard to IL-1Ra, the effect of GM-CSF was marginal.
by GM-CSF-treated neutrophils in response to EBV
Profile of EBV-induced IL-1 and IL-1Ra production by
Neutrophils were preincubated with or without 1 nM
neutrophils treated with GM-CSF
GM-CSF for 1 h at 377C and further incubated with or
without EBV for 3 h. These conditions were found toAdditional experiments were made using the optimal
conditions determined above to compare the effect of be optimal for IL-1b and IL-1Ra mRNA accumulation in
human neutrophils. Figure 3 is a representative autora-GM-CSF on the production and secretion of IL-1a, IL-1b,
and IL-1Ra by neutrophils in response to EBV. Neutro- diograph of three separate RNA preparations from three
different experiments. Membrane was probed with 32P-phils were preincubated with or without GM-CSF for 1 h
at 377C and further incubated with or without EBV for 6 labeled IL-1b and IL-1Ra cDNA. Compared to neutrophils
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TABLE 3
Effect of GM-CSF on the Production of IL-1 and IL-1Ra Induced by EBV in Human Neutrophils
Cell-associated Secreted
(pg/ml) (pg/ml)
Total IL-1 Ra Total IL-1
IL-1 Ra IL-1a IL-1b IL-1Ra IL-1a IL-1b (pg/ml) (pg/ml)
Diluent
Unstimulated 21,550 { 2411 2 { 1 8 { 2 3,582 { 1024 3 { 1 4 { 2 25,132 { 3198 17 { 3
EVBa 34,283 { 2114** 212 { 44** 379 { 64** 13,618 { 2556** 15 { 7 24 { 3** 47,901 { 3004** 630 { 103**
GM-CSF
Unstimulated 31,883 { 1424 23 { 10 69 { 12 13,413 { 2389 4 { 2 8 { 4 45,297 { 3009 104 { 20
EBVb 35,967 { 2038 717 { 92** 809 { 96** 24,291 { 3907* 23 { 6 55 { 10* 56,925 { 3243* 1604 { 159**
Note. Neutrophils were preincubated with diluent or with 1 nM GM-CSF for 1 h at 377C before incubation in medium alone or with EBV for 6 h
at 377C. Secreted and cell-associated IL-1 Ra, IL-1a, and IL-1b production was assessed by specific ELISAs. Results are expressed as pg/ml and
are the means of six separate experiments. Values obtained for neutrophils incubated with GM-CSF or EBV alone were compared to those for
unstimulated cells. Values significantly different are indicated by *P  0.05, **P  0.01. Pretreatment of GM-CSF with neutralizing antiserum
abrogated the enhancement of IL-1 and IL-1 Ra production induced by GM-CSF alone or in combination with EBV.
a Values obtained for neutrophils incubated with EBV alone were compared to those obtained for unstimulated cells.
b Values obtained for neutrophils pretreated with GM-CSF before EBV treatment were compared to those obtained in response to GM-CSF or
EBV alone.
incubated in medium alone, an increase in IL-1b and IL- present study suggests that GM-CSF can enhance the
host response against EBV by upregulating the IL-1 and1Ra mRNA levels was observed for neutrophils incu-
superoxide production by neutrophils.bated with EBV or GM-CSF alone. Pretreatment of neutro-
The main cellular source of GM-CSF in response tophils with GM-CSF prior to incubation with EBV did not
EBV was investigated with purified lymphocytes, mono-affect the levels of IL-1b or IL-1Ra mRNA, suggesting
cytes, or neutrophils. Under the conditions tested, onlythat the enhancing effect observed occurred at the trans-
monocytes were found to release GM-CSF. In addition,lational level. GM-CSF, however, upregulated EBV-in-
more than 90% of the GM-CSF produced was secretedduced IL-1a and b protein synthesis in these same cell
and thus readily available to perform its biological activ-preparations (data not shown).
ity. Since GM-CSF increases the IL-1 production induced
by EBV and IL-1 can induce GM-CSF release by mono-DISCUSSION
cytes (Sallerfors and Olofsson, 1992), these interactions
Neutrophils are of critical importance in host defense could serve to further upregulate the response of neutro-
against infectious organisms. In fact, these cells may phils to EBV by setting up an amplification loop. With
exert a significant influence on the outcome of invasion regard to the mechanisms involved in the regulation of
by such agents since they are abundant and rapidly mo- EBV-induced GM-CSF synthesis, our results suggested
bilized at the sites of infection. We recently demonstrated that gp350 of the viral envelope could be involved in this
that EBV binds to human neutrophils and stimulates cel- process. This was confirmed by experiments using the
lular activities, including total RNA and protein synthesis, neutralizing antibody 72A1, which is known to block the
homeotypic aggregation, and IL-1 and IL-1Ra gene ex- binding of gp350 to the EBV receptor. In addition, the
results obtained showed that UV-irradiated virus retainedpression (Beaulieu et al., 1995; Roberge et al., 1996). The
TABLE 4
Effect of GM-CSF on O02 Generation Induced by EBV in Human Neutrophils
Treatment
Donor Control GM-CSF EBV GM-CSF / EBV
1 0.66 { 0.07 3.13 { 0.86 1.23 { 0.11 5.59 { 0.67*
2 0.94 { 0.08 2.61 { 0.55 1.14 { 0.09 6.87 { 0.62*
3 0.81 { 0.10 0.90 { 0.26 0.71 { 0.10 2.61 { 0.23*
Note. Neutrophils (2 1 106/ml) were treated or not with GM-CSF (500 pM) for 1 h at 377C prior to stimulation with EBV or fMLP (1007 M). Results
are expressed in nmol/ml of O02 { SE.
* Data significantly different from EBV- or GM-CSF-treated cell controls (P  0.05) using unpaired two-tailed Student’s t test.
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suggest that enough IL-1Ra is produced to inhibit, at
least in part, the biologic effects of IL-1 on surrounding
cells and may reflect the immunosuppression associated
with EBV infection. In the present study, we demon-
strated the time-dependent modulatory effects of GM-
CSF on EBV-induced IL-1 and IL-1Ra production. Preincu-
bation of neutrophils with GM-CSF before EBV treatment
synergistically enhanced the production of IL-1a and IL-
1b, but poorly affected IL-1Ra production. It was reported
that an excess of IL-1Ra (100 times) is needed to abro-
gate the biologic effects of IL-1 on target cells by at least
50% (Arend, 1991; Dinarello and Thompson, 1991; and
reviewed in Dinarello, 1996). Interestingly, the results
presented herein suggest that pretreatment of neutro-
phils with GM-CSF may favor host response by altering
the ratio of IL-1Ra to IL-1 in favor of IL-1. In fact, the total
concentration of IL-1Ra was only 35 times that of IL-1.
Therefore, not enough IL-1Ra would be present to totally
inhibit the simultaneous effect of IL-1. The main IL-1 pro-
tein detected in EBV-treated neutrophils was located inFIG. 3. Northern blot analysis of IL-1b and IL-1Ra production by
the cell-associated materials. This could be of interestGM-CSF-treated neutrophils in response to EBV. Normal human blood
neutrophils (107/ml) were preincubated with or without 1 nM GM-CSF since both the cell-associated IL-1a and IL-1b could be
for 1 h at 377C and incubated with or without EBV for 3 h at 377C. liberated following death of the cell. In fact, following
Identical cell pellets equivalent to 40 1 106 neutrophils in each experi- such events, pro-IL-1a and pro-IL-1b are released and
mental condition were pooled and total RNA extracts prepared as de-
can be cleaved by extracellular proteases, leading totailed under Materials and Methods. Equivalent amounts of RNA (10
their mature biologically active forms (Dinarello, 1996;mg/lane) were size fractionated by denaturating agarose gel electro-
phoresis, blotted onto Hybond-N membranes, and sequentially probed Mosley et al., 1987). Such a release of IL-1, in large
with 32P-labeled IL-1b, IL-1Ra, and GAPDH cDNA. The results pre- quantity, could therefore counter the suppressive effect
sented are from one experiment and are representative of three sepa- of IL-1Ra.
rate experiments.
Another mechanism by which the neutrophil can par-
ticipate in the destruction of invading microorganisms is
through the activation of its oxidative or respiratory burst.the full GM-CSF-inducing potential of the native particle,
suggesting that a contact between the cell and a struc- The immediate product of the reaction is superoxide
anion (O02 ). In the present study, we showed that GM-tural protein of the virus is sufficient to induce the release
of GM-CSF. The binding sites for EBV on monocytes CSF enhances the superoxide production by neutrophils
in response to EBV. The fact that neutrophils are capablehave not been characterized yet. However, our previous
experiments suggest that EBV can recognize a molecule of producing O02 in response to EBV after treatment with
GM-CSF may represent a mechanism by which thesedistinct from CD21 (Beaulieu et al., 1995; Gosselin et
al., 1991). This hypothesis was also supported by others cells can neutralize viral invasion.
The specificity of the effects of GM-CSF was confirmed(Bejarano et al., 1990; Hedrick et al., 1992; Sauvageau et
al., 1990; Watry et al., 1991). by abrogation of the enhancing effect of GM-CSF by neu-
tralizing anti-GM-CSF antibodies. Although the mecha-IL-1 is one of the cytokines that are known to be inti-
mately implicated in the host response to infection and nisms responsible for the modulatory effects of GM-CSF
have not been specifically addressed in this study, itinjury, and its biological activity is closely regulated by
a naturally occurring IL-1 inhibitor, named IL-1Ra (for appears that the upregulatory effect occurs at the post-
transcriptional and/or translational levels. The fact thatreview see Dinarello, 1996). It is now well accepted that
both IL-1 and IL-1Ra are simultaneously produced by the cytokine protein levels were increased in the ab-
sence of changes in mRNA levels is suggestive of ahuman neutrophils and that the expression of these two
cytokines can be uncoupled. Thus, the production of greater cellular RNA stability or a more effective transla-
tion of IL-1 and IL-1Ra mRNAs. This conclusion is sup-these two cytokines needs to be tightly regulated to per-
mit host defense or to prevent inappropriate or prolonged ported by the fact that although GM-CSF enhances IL-1
and IL-1Ra protein production in response to EBV, accu-synthesis of biologically active IL-1. In this respect, we
recently demonstrated that although EBV induces IL-1 mulation of IL-1b and IL-1Ra mRNA is unaffected. Further
experiments will be required to clarify the exact mecha-and IL-1Ra gene expression in neutrophils, much more
IL-1Ra than IL-1a or IL-1b is secreted by neutrophils in nisms underlying these findings.
In summary, the results of the present study clearlyresponse to EBV (Roberge et al., 1996). These results
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phils by substimulatory concentrations of phorbol esters: A noveldemonstrate that interaction of EBV with GM-CSF-treated
role for protein kinase C and tyrosine phosphorylation in the up-neutrophils increases the superoxide production by neu-
modulation of signal transduction. Cell. Signalling 4, 511–523.
trophils and favors the production of IL-1 over that of its Gosselin, J., Flamand, L., D’Addario, M., Hiscott, J., and Menezes, J.
antagonist, IL-Ra. Local production of GM-CSF by mono- (1992a). Infection of peripheral blood mononuclear cells by herpes
simplex and Epstein–Barr viruses: Differential induction of interleu-cytes at an inflammatory site could serve to potentiate
kin-6 and tumor necrosis factor-a. J. Clin. Invest. 89, 1849–1856.the host defense mechanisms directed toward the de-
Gosselin, J., Flamand, L., D’Addario, M., Hiscott, J., Stefanescu, I., Ab-struction of the infectious virus. While the clinical signifi-
lashi, D. V., Gallo, R. C., and Menezes, J. (1992b). Modulatory effect
cance of these results remains to be determined, we of Epstein–Barr, herpes simplex, and human herpes-6 viral infections
believe that the differential production of IL-1Ra and IL- and coinfections on cytokine synthesis: A comparative study. J. Immu-
nol. 149, 181–187.1 observed in neutrophils treated with GM-CSF could
Gosselin, J., Menezes, J., D’Addario, M., Hiscott, J., Flamand, L., La-have important biologic effects.
moureux, G., and Oth, D. (1991). Inhibition of tumor necrosis factor-
a transcription by Epstein–Barr virus. Eur. J. Immunol. 21, 203–208.
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